Name: Rhizen Pharmaceuticals S.A. - BioCentury Company Profiles - BCIQ
Creator: Biocentury

signInButton

SIGN IN

Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Please note, you are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry. Request a trial to unlock the full value of BCIQ.

REQUEST A FREE TRIAL

AcquiredOrMerged

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.

If you believe a company has been archived in error, please contact us at 

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.\nIf you believe a company has been archived in error, please contact us at \nsupport@biocentury.com\n.

Cat-H(AcquiredorMerged)

Historical deals and financings can be found by searching the organization's name in the BCIQ <DEALS> and <FINANCING> Modules.

Default (Company Type Blank)

CategoryHDefault (Company Type Blank)

NonBioPharma

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.

Cat-H(NonBioPharma)

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.\n

Rhizen Pharmaceuticals S.A.

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

TG reports response rate of 52% for lymphoma candidate

TG aims for accelerated approval of lymphoma candidate

TG aims for accelerated approval of lymphoma candidate

TG won't seek accelerated approval of CLL combo

TG Therapeutics reports Phase II data for umbralisib in CLL

TG Therapeutics completes enrollment in Phase III UNITY-CLL trial

TG Therapeutics completes enrollment in Phase III UNITY-CLL trial

DSMB recommends continuation of TG's ublituximab Phase III trial

DSMB recommends continuation of TG's TGR-1202 Phase III trial